Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.

REDWOOD CITY, Calif., July 25, 2017 /PRNewswire/ -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distribution of Roxwood products in the United States.

"This partnership with Abbott's vascular business is a major milestone for Roxwood that allows far more patients to benefit from our catheter portfolio used during complex coronary procedures," said Mehrdad Farhangnia, chief executive officer, Roxwood Medical. "We have an amazing team at Roxwood, and are excited to work with Abbott to help patients suffering from advanced coronary artery disease."

Roxwood's anchoring catheters (CenterCross® Ultra, MultiCross®) and microcatheters (MicroCross®) offer minimally invasive platforms for physicians to percutaneously treat patients with chronic blockages by facilitating guidewire access across the blockage, often times averting an invasive bypass procedure. Roxwood's anchoring and microcatheters will join Abbott's other product offerings including the XIENCE™ drug eluting stent and the OPTIS™ integrated optical coherence tomography system.

"Our XIENCE stent is unparalleled when it comes to safety in complex PCI cases," said Jim Mayberry, divisional vice president of U.S. Vascular Sales, Marketing and Operations, Abbott. "The inclusion of Roxwood products in our industry-leading portfolio allows Abbott to provide a comprehensive solution for the most difficult cases, including chronic total occlusions."

Percutaneous coronary interventions (PCI) are considered complex when patients have other chronic conditions such as diabetes or advanced kidney disease, when multiple vessels are involved, or if a vessel is severely blocked. The majority of PCIs performed today in the United States are considered complex in nature.¹

About Roxwood Medical
Roxwood Medical is a developer of innovative solutions that tackle some of the most complex procedures in interventional cardiology. The company has developed a platform of front-line catheters to help patients with severe coronary and peripheral arterial disease. The company's novel CenterCross® Ultra and MultiCross® catheters utilize an atraumatic nitinol anchoring mechanism to simplify guidewire access across arterial blockages. Roxwood's MicroCross® platform provides clinicians an ultra-low profile microcatheter to access the most challenging coronary and peripheral anatomies with optimum guidewire support. Roxwood's products have regulatory clearance in major markets around the globe.

For more information, please visit www.roxwoodmedical.com or follow on Twitter @RoxwoodMedical.

Contact:
Mehrdad Farhangnia
CEO, Roxwood Medical
Phone     650-779-4559

¹ Krone, RJ, et al. Evaluation of the ACC/AHA and the SCAI Lesion Classification System in the Current Stent Era of Coronary Interventions (From the ACC NCDR), The American Journal of Cardiology Vol. 92 August 15, 2003.

SOURCE Roxwood Medical Inc.